Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), with little toxicity overlap. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens. The present studies further characterize efficacy and safety of the XELOX regimen.
INTRODUCTION
Intravenous fluorouracil (FU) has been the mainstay of chemotherapy for metastatic colorectal cancer (MCRC) for many years. Prolonged infusion of FU in combination with the biomodulator leucovorin (LV) has an improved safety and efficacy profile compared with the bolus FU/LV, [1] [2] [3] but the inconvenience and morbidity associated with long-term central venous access emphasized the need for alternative regimens. Capecitabine is an oral fluoropyrimidine that was rationally designed to generate FU preferentially at the tumor site, via a threestep enzymatic process that exploits the significantly higher activity of thymidine phosphorylase (TP) in tumors, compared with healthy tissue. 4 Twice-daily dosing of oral capecitabine obviates the drawbacks of prolonged infusions of FU. A prospective, integrated analysis of two large, randomized phase III trials in MCRC demonstrated that capecitabine monotherapy achieves significantly higher tumor response rates compared with FU/LV (Mayo Clinic regimen) (26% v 17%, P Ͻ .0002). [5] [6] [7] Capecitabine also had an improved safety profile versus FU/LV (Mayo Clinic regimen), causing significantly less diarrhea, stomatitis, nausea, alopecia, and neutropenia, leading to less neutropenic fever/ sepsis and associated hospitalizations. 8 Hand-foot syndrome (HFS) occurred more frequently with capecitabine than with FU/LV, but this cutaneous side effect is never life-threatening and rarely led to hospitalization. A large phase III trial (n ϭ 1,987) is also evaluating capecitabine as adjuvant treatment for patients with Dukes' C colon cancer. A planned safety analysis, conducted 19 months following the enrollment of the last patient, has confirmed that the improved safety profile of capecitabine versus intravenous (IV) FU/LV observed in the metastatic setting is mirrored with adjuvant treatment. 9 Capecitabine is therefore a highly active, more convenient, and better-tolerated alternative to FU/LV in colorectal cancer therapy.
Infused FU/LV in combination with oxaliplatin, a third generation platinum analog, proved more effective than FU/LV alone in the first-and second-line treatment of MCRC. Addition of oxaliplatin to FU/LV therapy significantly increased response rates and time to disease progression (TTP) compared with FU/LV in the first-line treatment of colorectal cancer in three randomized studies [10] [11] [12] and as second-line therapy versus FU/LV. 13 Recently, a large cooperative group trial (N9741) showed significant improvements in response rate, TTP, and overall survival with oxaliplatin plus infused FU/LV versus irinotecan plus bolus FU/LV. 14 Despite the increased efficacy associated with infused FU/LV plus oxaliplatin, the administration schedules for the FU component are inconvenient for both patients and healthcare professionals. These require two bolus injections plus two 22-hour infusions every 2 weeks, 10 or 5 days of continuous infusion with chronomodulation equipment every 3 weeks, 11 or weekly 24-hour infusion.
12 Because capecitabine has already demonstrated its ability to replace FU/LV as a highly effective and more convenient treatment for colorectal cancer, there is a strong rationale for investigating the efficacy and safety of capecitabine in combination with oxaliplatin.
A phase I study showed that the combination of capecitabine with oxaliplatin (XELOX) is feasible and established the recommended dose regimen as IV oxaliplatin 130 mg/m 2 on day 1 followed by oral capecitabine 1,000 mg/m 2 twice daily, days 1 to 14, in a 3-week cycle. 15 A xenograft study has also been performed to further elucidate the preclinical rationale for the XELOX combination. In addition, the current international, phase II study was conducted to evaluate further the efficacy and safety of this regimen as first-line therapy for patients with MCRC and thus determine the potential of capecitabine to replace FU/LV as the standard combination partner for oxaliplatin.
PATIENTS AND METHODS

Evaluation of Capecitabine Plus Oxaliplatin in a Human Cancer Xenograft Model
The effect of capecitabine and oxaliplatin, alone and in combination, on tumor growth and expression of TP in a human colon cancer xenograft model was investigated. The human colon cancer xenograft model, CXF280, was provided by H.H. Fiebig (Freiburg University, Freiburg, Germany). Tumor tissue from human colon cancer CXF280 was inoculated subcutaneously into BALB/c nu/nu mice. Drugs were administered when tumor volume (1/2 ϫ length ϫ width ϫ width) reached approximately 0.3 to 0.5 cm 3 . To evaluate the antitumor effect of capecitabine and oxaliplatin, tumor size and body weight were measured twice a week. Capecitabine, dissolved in 40 mmol/L citrate buffer (pH 6.0) containing 5% gum arabic, was administered orally for 14 consecutive days. Oxaliplatin in 5% glucose solution was given intravenously on day 1. Tumor TP was measured by enzyme-linked immunosorbent assay, with monoclonal antibodies specific for human TP as described previously.
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Phase II Study Design
This was a large, open-label, phase II study, conducted at 13 centers in Europe, Israel, and North America. The primary end point was overall response rate as assessed by the investigator. Secondary end points included independently reviewed response rate, TTP, overall survival, 1-year survival, and safety. The study was performed in accordance with the Helsinki declaration and its amendments, and ICH-GCP guidelines. 17 All patients provided written, informed consent.
Patients
Patients aged 18 to 75 years with measurable, histologically confirmed metastatic or locally advanced colorectal cancer were eligible for the study. Patients were required to be ambulatory and have a Karnofsky performance status of Ͼ 70%, with a life expectancy of Ն 3 months. Prior chemotherapy for advanced disease was not permitted, but adjuvant or neoadjuvant chemotherapy was allowed, providing it was completed at least 6 months before start of study treatment. Exclusion criteria included prior therapy with capecitabine, oxaliplatin, or irinotecan, history of previous malignancy within 5 years, clinically significant cardiac disease, evidence of CNS metastases, radiotherapy or surgery within 4 weeks before treatment, neutropenia (Ͻ 1.5 /L), thrombocytopenia (Ͻ 100/ L), severe renal function impairment (creatinine clearance Ͻ 30 mL/min), or abnormal liver function. Pregnant or lactating women were excluded from the study; women of childbearing potential and sexually active males were required to agree to practice appropriate and adequate contraception.
Study Assessments
Prestudy screening assessments included a full medical history, vital signs and physical measurements, and hematologic and blood chemistry tests. Tumor assessments were performed by computed tomography scan, x-ray, and/or magnetic resonance imaging during screening, after the first three cycles of treatment, then after every two cycles of treatment until disease progression or withdrawal from study medication. In patients whose disease had not progressed when stopping treatment, tumor assessments were performed every 3 months until progression. In addition to investigator assessment, tumor imagery was evaluated by an independent review committee (IRC), using x-ray, magnetic resonance imaging, or computed tomography scans. Investigators and the IRC assessed the same scans. In addition, survival was monitored at intervals of every 3 months in each patient leaving the study. Tumor response was assessed according to WHO criteria 18 and confirmed at least 4 weeks later by the same evaluation. TTP was defined as the interval between the first dose of study treatment and the first recording of disease progression or death.
Adverse events, including neurosensory toxicity and HFS, were classified by National Cancer Institute Common Toxicity Criteria version 2.
Treatment
Treatment comprised IV oxaliplatin 130 mg/m 2 (diluted in a 5% glucose solution) day 1 then oral capecitabine 1,000 mg/m 2 twice daily from the evening of day 1 to the morning of day 15, followed by a 7-day treatment-free interval, in a 3-week cycle. Pyridoxine prophylaxis or treatment for HFS was not permitted during this study, given that pyridoxine has been reported to reduce the efficacy of cisplatin. 19 The capecitabine starting dose was reduced to 75% of the standard capecitabine starting dose in patients with moderate renal impairment (30 mL/min Յ creatinine clearance Ͻ 50 mL/min). The dose of capecitabine was adjusted for adverse events of grade 2 or higher intensity, according to the standard scheme, described in detail by Blum et al. 20 The dose of oxaliplatin was reduced for grade 3 vomiting, grade 3 or 4 thrombocytopenia, or grade 4 neutropenia, and for paresthesiae with pain or functional impairment Ͼ 7 days, or paresthesiae with pain persistent between cycles. For paresthesiae with functional impairment persistent between cycles, oxaliplatin was discontinued.
The planned number of treatment cycles was 11, but patients maintaining a response or stable disease after this time could continue treatment at the discretion of the investigator. Patients could also continue capecitabine monotherapy after discontinuation of oxaliplatin irrespective of the number of cycles already received.
Statistical Analysis
The efficacy analyses were based on the intent-to-treat population. The primary end point was overall confirmed response rate, as assessed by the investigators. The 95% CI for response risk was calculated. According to the method of Fleming, 21 80 assessable patients were required to demonstrate a 40% overall response rate with a power of 90%. TTP and survival were estimated by Kaplan-Meier analysis. Safety was analyzed in all patients who received at least one dose of study medication.
Clinical cutoff for the study analysis was January 15, 2003. A minimum follow-up of 24 months had been reached in all patients.
RESULTS
Capecitabine and Oxaliplatin in a Preclinical Xenograft Model
In a human tumor xenograft model, the combination of capecitabine and oxaliplatin inhibited the in vivo growth of CXF280 human colon cancer more effectively than either agent alone, administered at their maximum-tolerated doses (Fig 1) . Toxicity in terms of weight loss did not appear to be additive in the capecitabine plus oxaliplatin group. Furthermore, oxaliplatin upregulated TP expression in CXF280 tumor tissue (Fig 2) . The high activity observed with capecitabine and oxaliplatin may be due, therefore, to upregulation of TP. The fact that toxicity (monitored by assessing body weight loss) was not enhanced with the XELOX combination may support the hypothesis that TP upregulation is a tumor-specific phenomenon.
Patient Demographics
A total of 96 patients were recruited between July 2000 and March 2001, from 13 centers in seven countries (Belgium, Canada, France, Germany, Israel, Italy, Spain, and the United Kingdom). The patient profile was typical of a first-line MCRC trial population: approximately half of the patients (54%) had multiple metastases, with liver, lymph nodes, and lung being the most frequent sites of metastases (Table 1) . One enrolled patient initially diagnosed with a colorectal cancer liver metastasis was subsequently found to have a hemangioma, rather than metastatic disease. The median time from the primary diagnosis of colorectal can- cer to inclusion was 2.9 months. Of the 27 patients (28%) who had received prior adjuvant or neoadjuvant chemotherapy, 26 had received IV FU, and one had received oral tegafur/uracil. Eleven patients (11%) had received prior radiotherapy.
Treatment
A total of 39 patients (39%) completed the planned 11 cycles of either XELOX or capecitabine monotherapy, of whom 21 (22%) continued with either XELOX or capecitabine monotherapy after 11 cycles. A median of eight cycles of XELOX combination therapy (range, one to 26 cycles) were administered, and patients received a median of two cycles of capecitabine monotherapy after discontinuation of oxaliplatin (range, one to 39 cycles). Table 2 shows the numbers of patients receiving XELOX or capecitabine monotherapy at each cycle.
Efficacy
All efficacy analyses were conducted on the intent-totreat population, which comprised all patients enrolledthat is, none of the enrolled patients withdrew before receiving treatment. All patients were followed up for a minimum of 24 months. An objective response was observed in 53 patients (55%; 95% CI ,45% to 65%; Table 3) , with complete response in two patients (2%). All objective responses were confirmed at least 4 weeks after first observation. Disease stabilization was achieved in a further 30 patients (31%; 95% CI, 22% to 42%). Notably, disease stabilization lasted longer than 3 months from start of treatment in all of these patients.
The response rate by IRC assessment was 45% (43 patients; 95% CI, 35% to 55%). Concordance between investigator and IRC was high, with identical assessments in 63 of the 85 patients (74%) for whom an assessment by both investigator and IRC was available. The majority of discrepancies were between patients classified as showing partial response or stable disease.
Response rates were analyzed in patient subpopulations (Fig 3) . XELOX achieved consistently high (Ͼ 50%) response rates in all patient subpopulations studied.
After a minimum follow-up of 24 months, the median TTP in the intent-to-treat population was 7.7 months (95% CI, 6.4% to 8.6%; Fig 4) . Median overall survival was 19.5 months (95% CI, 15.3% to 21.6%; Fig 5) . The survival rate was 70% at 1 year and 30% at 2 years. Abbreviations: KPS, Karnofsky performance status; FU, fluorouracil; IV, intravenous.
‫ء‬
A single lesion in one patient originally recorded as a metastatic site was subsequently found to be a hemangioma.
†With or without biomodulating agent. 
Poststudy Treatment
A total of 66 patients (69%) received second-line and 35 (36%) received third-line chemotherapy. The most common second-line chemotherapy was irinotecan (48 patients; 50%), either as monotherapy or in combination with FU (Table 4) . Second-line capecitabine was given to 11 patients after disease progression (including four who received further XELOX). Twelve patients (13%) received palliative radiotherapy, and five underwent surgery, including four patients who underwent partial hepatic resection and one who underwent a partial liver and lung resection.
Safety
Safety was evaluated in all patients who received treatment (n ϭ 96). Of the 59 patients withdrawing during the treatment phase (the first 11 cycles), the majority (35 patients) withdrew because of disease progression ( Table 5) .
The most common (Ͼ 20%) treatment-related adverse events are shown in Figure 6 . Sensory neuropathy, a frequent side effect of oxaliplatin, was the most common treatment-related adverse event, occurring in 85% of patients. The majority of neuropathy was mild to moderate, with only 17% experiencing cumulative neurotoxicity (grade 3 or 4). The majority of treatment-related adverse events were mild to moderate in intensity. The most common grade 3 or 4 treatment-related adverse events were sensory neuropathy (17%), diarrhea (16%), and nausea or vomiting (13%; Fig 7) . Only five patients (5%) experienced grade 4 treatment-related adverse events. HFS was experienced by 35 patients (36%), but at grade 3 intensity in only three patients (3%).
Grade 3 elevations in laboratory parameters were rare, comprising neutropenia (7%), thrombocytopenia (4%), anemia (1%), and hyperbilirubinemia (4%). Hyperbilirubinemia was an isolated laboratory abnormality and was not accompanied by grade 3 or 4 elevations in alkaline phosphatase or liver transaminases. No grade 4 elevations in laboratory abnormalities were observed. XELOX demonstrated a similar favorable safety profile among the subgroups of patients aged Ն 65 years or younger than 65 years. Stomatitis was the only treatmentrelated adverse event more common in patients at least 65 years old than those younger than 65 years (34% v 17%, respectively), but no patients in either age group experienced grade 3 or 4 stomatitis. Overall, there was a similar incidence of grade 3 or 4 treatment-related adverse events in the two age groups (64% of patients younger than 65 years and 59% of patients 65 years or older). Among the subgroups of patients at least 65 years old or younger than 65 years, there were no significant differences in the incidences of any grade 3 or 4 treatment-related adverse events, including peripheral sensory neuropathy (15 v 18%, respectively), diarrhea (14 v 18%, respectively), nausea or vomiting (12 v 14%, respectively), neutropenia (6 v 5%), and HFS (6 v 0%, respectively).
Forty-eight patients (50%) received full doses of capecitabine and oxaliplatin throughout the study. Dose reduction was required for capecitabine alone in 14 patients (15%), for oxaliplatin alone in 12 patients (13%), and for both agents in 22 patients (23%). The majority of dose reductions were by one level (reduction to 75% of starting dose of capecitabine and/or 100 mg/m 2 oxaliplatin). Only seven patients (7%) required a second level dose reduction, to 50% of starting dose of capecitabine and/or 80 mg/m 2 oxaliplatin. Adverse events most commonly leading to dose reduction were myelosuppression and neurotoxicity. The incidence of dose reduction was similar in the subgroups of male and female patients and those younger than 65 years or at least 65 years (data not shown).
Three deaths occurred during or within 28 days of withdrawal from study treatment during the planned 11 treatment cycles, but only one of these was considered possibly related to treatment (pulmonary fibrosis, a rare but known side effect of oxaliplatin, which occurred during cycle 8). The other two deaths were caused by colonic perforation and cardiac arrest, both during cycle 1. Sixty-day all-cause mortality was therefore 2%.
DISCUSSION
The XELOX regimen is a rational combination treatment. The addition of oxaliplatin to infused FU/LV chemotherapy results in higher response rates and TTP in both first-and second-line treatment of advanced colorectal cancer. Oral capecitabine monotherapy has previously shown superior antitumor activity to bolus FU/LV (Mayo Clinic regimen) in this setting, with higher response rates (26% v 17%, P Ͻ .0002) and at least equivalent TTP and overall survival in two large randomized studies. [5] [6] [7] The high clinical activity of the XELOX combination may be explained in part by the preclinical data suggesting that capecitabine and oxaliplatin have supra-additive activity in combination. Our studies show that the combination of capecitabine and oxaliplatin inhibit the in vivo growth of CXF280 human colon cancer more effectively than either agent alone. Furthermore, oxaliplatin upregulates TP, the key enzyme involved in tumor-specific generation of FU with capecitabine, in CXF280 tumor tissues. Oxaliplatin-induced upregulation of TP could therefore result in supra-additive activity with XELOX that may Abbreviation: MCRC, metastatic colorectal cancer.
‫ء‬
Adverse events most commonly leading to withdrawal from the study were thrombocytopenia, asthenia, and diarrhea.
†One patient had a hepatic resection, and one patient achieved maximal response and was removed from the study.
not occur with IV infused oxaliplatin with FU and leucovorin (FOLFOX) combinations.
This clinical study was undertaken to further evaluate the combination of XELOX as first-line therapy for MCRC. XELOX achieved a high response rate of 55%, with an additional 31% of patients maintaining stable disease for at least 3 months. Moreover, subgroup analysis showed that the response rate remained high (Ͼ 50%) irrespective of patient and disease characteristics for all subgroups explored, which included those younger than 65 years or at least 65 years, and those with Karnofsky performance status Յ 80 or Ͼ 80, prior adjuvant therapy, and liver or lung metastases. These efficacy results compare favorably with the randomized studies of FU/LV with or without oxaliplatin, 10-12 which demonstrated significant improvements for the combination (FOLFOX4) compared with FU/LV alone. XELOX achieves similar response rates and progression-free and overall survival to all of the regimens combining protracted FU/LV infusion with oxaliplatin. Capecitabine and oxaliplatin do not have overlapping key toxicities, and the combination was well tolerated even with the long treatment duration. The safety profile of XELOX was similar to that of FU/LV plus oxaliplatin, with a lower incidence of grade 3 or 4 neutropenia. Only three patients experienced grade 3 HFS. The low incidence of grade 3 HFS with XELOX may be due to the 20% lower dose of Xeloda used in the XELOX trial compared with the monotherapy studies. However, HFS is thought to be due to chronic daily exposure, and it is also possible that oxaliplatin-induced neurotoxicity may be masking the symptoms of HFS. In addition, XELOX demonstrated a similar safety profile in patients younger than 65 years or at least 65 years. Fifty percent of patients received the full doses of capecitabine and oxaliplatin throughout the study. The median time to first dose reduction was identical for both agents (2.9 months). There was a similar incidence of dose reduction in males and females younger than 65 years or at least 65 years.
The data therefore indicate that three-times-weekly XELOX is a highly effective regimen for the first-line treatment of advanced colorectal cancer and that capecitabine has strong potential to replace FU/LV as the optimal combination partner for oxaliplatin. The XELOX dose schedule of capecitabine 1,000 mg/m 2 twice daily with oxaliplatin 130 mg/m 2 had been previously identified in a phase I dose-escalation study.
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Other regimens with capecitabine and oxaliplatin have been evaluated. Before completion of the dose-escalation study, another phase II trial evaluated a higher dose of capecitabine, 1,250 mg/m 2 twice daily (the recommended dose for capecitabine monotherapy), in combination with oxaliplatin 130 mg/m 2 in patients with pretreated and previously untreated MCRC. 22 While a response rate of 49% was obtained in patients receiving the combination as firstline therapy, the incidence of grade 3 or 4 diarrhea was 33% in treatment-naïve patients and 50% in pretreated patients. Although the authors recommend the full dose of both agents for treatment of patients with advanced CRC, more than 25% of the chemotherapy-naïve population required a capecitabine dose reduction after the first cycle. A randomized, phase II trial has evaluated two schedules of capecitabine plus oxaliplatin as first-line therapy in 89 patients with MCRC. 23 Patients were randomly assigned to receive a dose-intensified regimen (capecitabine 1,750 mg/m 2 twice daily on days 1 to 7 and 14 to 21 plus oxaliplatin 85 mg/m 2 on days 1 and 14, every 28 days) or XELOX as given in the present study (capecitabine 1,000 mg/m 2 twice daily days 1 to 14 plus oxaliplatin 130 mg/m 2 on day 1, every 21 days). No formal prospective comparison of efficacy in the two treatment groups was planned and the study was not powered statistically for such a comparison. Both regimens were active, achieving response rates of 55% and 42%, with median progression-free survival of 10.5 and 6.0 months, respectively. However, in the absence of data from a prospective, randomized, phase III comparison, no conclusions about the efficacy and safety of the dose-intensified regimen relative to XELOX can be drawn. Another phase II study has evaluated a lower dose of capecitabine (750 mg/m 2 twice daily) than used in the XELOX regimen.
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This regimen achieved a response rate of only 34% in 35 patients treated. In summary, the dose of 1,000 mg/m 2 capecitabine twice daily in combination with oxaliplatin, as used in the XELOX regimen, achieves high efficacy while maintaining a good safety profile. The XELOX regimen has demonstrated similar efficacy and safety to FOLFOX. Interestingly, the incidence of grade 3 or 4 neutropenia is lower with the XELOX regimen than with the FOLFOX4 regimen (7% v 42% to 47%), as is the incidence of febrile neutropenia (0% v 1% to 4%).
10,14 In addition, XELOX requires only one clinic visit per 3-week cycle for a 2-hour infusion of oxaliplatin. This constitutes a marked advantage over regimens combining infused FU/LV and oxaliplatin in terms of the impact on patients' daily lives and convenience for both patients and caregivers. With these regimens, FU/LV is administered in two 22-hour infusions over 3 days every 2 weeks, 10 a 5-day chronomodulated infusion every 3 weeks, 11 or a weekly 24-hour infusion. 12 In patients with MCRC, for whom treatment is essentially palliative, these protracted infusion times represent a significant portion of the patient's remaining life span. In addition, patients are exposed to the potential complications of central venous access. The simplified XELOX regimen is thus likely to have important implications for patients' well-being and autonomy.
In summary, this study shows that XELOX is a highly effective therapy for patients with MCRC. Response rates, time to progression, and overall survival compare favorably with previous studies of FU/LV/oxaliplatin, and the XELOX combination offers substantially improved convenience and is less disruptive for patients. Capecitabine therefore could replace FU/LV as the standard combination partner for oxaliplatin in this setting. Phase III evaluation of XELOX versus FU/LV plus oxaliplatin in both the first-and second-line settings is ongoing, as is evaluation of the XELOX regimen as adjuvant treatment for Dukes' C colon carcinoma. In addition, the XELOX regimen offers a novel, well-tolerated, and active backbone for incorporation of innovative targeted agents such as the EGFRdirected drugs gefitinib, erlotinib, and cetuximab, or the antiangiogenic monoclonal antibody bevacizumab.
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